Goel Deepak, Shangari Sushant, Mittal Manish, Bhat Ashwani
Department of Neurology, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.
Brain Circ. 2024 Mar 21;10(1):51-59. doi: 10.4103/bc.bc_56_23. eCollection 2024 Jan-Mar.
Stroke is a leading cause of morbidity and mortality worldwide and a leading cause of disability. None of the neuroprotective agents have been approved internationally except edaravone in Japanese guidelines in acute ischemic stroke. We here discuss that there are two types of endogenous defense mechanisms (EDMs) after acute stroke for neuromodulation and neuroregeneration, and if both can be activated simultaneously, then we can have better recovery in stroke.
We aimed to study the effect of combination of neuroprotection therapies acting on the two wings of EDM in acute large-vessel middle cerebral artery (LMCA) ischemic stroke.
Sixty patients of LMCA stroke were enrolled and randomized within 72 h into two groups of 30 patients each. The control group received standard medical care without any neuroprotective agents while the intervention group received standard medical care combined with oral citicoline with vinpocetine for 3 months with initial 1 week intravenous and edaravone and cerebrolysin injection, started within 72 h of onset of stroke. Patients were assessed on the basis of the National Institutes of Health Stroke Scale, Fugl-Meyer Assessment Score, Glasgow Coma Scale, and Mini-Mental Status Examination at admission, discharge, and after 90 days.
The intervention group showed significant and early improvements in motor as well as cognitive recovery.
Combination therapy for neuroprotection which is acting on two pathways of EDM can be useful in functional recovery after acute ischemic stroke.
中风是全球发病和死亡的主要原因,也是致残的主要原因。除依达拉奉在日本急性缺血性中风指南中被批准外,尚无神经保护剂在国际上获得批准。我们在此讨论急性中风后存在两种内源性防御机制(EDM)用于神经调节和神经再生,如果两者能同时被激活,那么中风患者就能获得更好的恢复。
我们旨在研究作用于EDM两翼的神经保护疗法联合应用对急性大脑中动脉(LMCA)大血管缺血性中风的影响。
纳入60例LMCA中风患者,在72小时内随机分为两组,每组30例。对照组接受标准医疗护理,不使用任何神经保护剂,而干预组接受标准医疗护理,并联合口服胞磷胆碱和长春西汀3个月,最初1周静脉注射依达拉奉和脑蛋白水解物注射液,在中风发作后72小时内开始使用。在入院时、出院时和90天后,根据美国国立卫生研究院卒中量表、Fugl-Meyer评估评分、格拉斯哥昏迷量表和简易精神状态检查对患者进行评估。
干预组在运动和认知恢复方面均显示出显著且早期的改善。
作用于EDM两条途径的神经保护联合疗法对急性缺血性中风后的功能恢复可能有用。